MeiraGTx Holdings plc (MGTX)
MGTXNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$9.55
+0.0600 (+0.63%) today
Regular session, Nov 10, 12:21 PM ET
- Market cap
- $917.21m
- P/E
- 13.4
- EPS, last 4 quarters
- $0.7100
- Dividend yield
- –
- Day range
- $9.30 to $9.68
- 52-week range
- $6.62 to $15.35
- Average volume
- 830.1k
- Previous close
- $9.49
Analysts
5 coveringBuy4 buy, 1 hold, 0 sell
Targets a year out average $22.40, +134.6% from here
Earnings
next estimate $-0.4600Next report Nov 12, 2026
Sep 2025
-24.0%
Dec 2025
+131.7%
Mar 2026
-32.6%
Jun 2026
+538.5%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $410.0k | $75.36m | $293.0k | $321.43m |
| Gross profit | $97.0k | $74.89m | $95.0k | $314.27m |
| Operating income | -$46.05m | $26.47m | -$40.82m | $244.43m |
| Net income | -$50.51m | $15.09m | -$46.31m | $160.67m |
Last four quarters: revenue $397.50m, margin 19.9%, free cash flow $10.47m
News
8 latest- Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.The Motley Fool · Aug 31, 2026
- MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass EstimatesZacks · Aug 13, 2026
- TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue EstimatesZacks · Aug 12, 2026
- Pacira (PCRX) Tops Q2 Earnings and Revenue EstimatesZacks · Aug 4, 2026
- Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?Zacks · Jul 15, 2026
- What This MeiraGTx Insider Sale Might Mean With Two Drug Filings NearThe Motley Fool · Jul 12, 2026
- MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?Zacks · Jul 8, 2026
- MeiraGTx Enters $400 Mln Investment Deal With Oberland Capital RTTNews · Jul 7, 2026
The company
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline with four late-stage clinical programs. Each of these programs use local delivery of small doses resulting in disease modifying effects in both inherited and more common diseases, in the eye, radiation-induced xerostomia, and Parkinson's disease. MeiraGTx uses its innovative technology in optimization of capsids, promoters and novel translational control elements to develop best in class, potent, safe viral vectors. MeiraGTx's broad pipeline is supported by end-to-end in-house manufacturing. MeiraGTx has built the most comprehensive manufacturing capabilities in the industry, including two that are licensed for GMP viral vector production and a GMP QC facility with clinical and commercial licensure.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- meiragtx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.